FDA extends review of XenoPort-Glaxo pain drug

The Food and Drug Administration needs three more months to review an application to a neuropathic pain drug being developed by XenoPort Inc. and GlaxoSmithKline PLC, the companies said.

The Associated Press

NEW YORK —

The Food and Drug Administration needs three more months to review an application to a neuropathic pain drug being developed by XenoPort Inc. and GlaxoSmithKline PLC, the companies said.

XenoPort and GlaxoSmithKline said late Friday the FDA should complete its review of the drug, called gabapentin enacarbil, by Feb. 9, 2010. The review period was scheduled to end Monday. The FDA wanted the companies to develop a strategy to evaluate the drug's risks, and after GlaxoSmithKline submitted that strategy, the agency needed additional time to review it.

XenoPort is based in Santa Clara, Calif., and GlaxoSmithKline is headquartered in London. In premarket trading, XenoPort stock rose 7 cents to $18.21 from $18.14.

E-mail article Print view Share

More Business & Technology

Nintendo re-enlists Mario, savior of video-game industry

Verizon-Frontier deal stirs concern among consumers

Brier Dudley: 'Guitar Hero' founder excited about future

Gaps for consumers in Democrat health care bills

Hutch gets $10M from Bezos family for immunotherapy research

More Business & Technology headlines...

Comments (0)

Hide comments / Show comments

No comments have been posted to this article. Start the conversation.

Read all comments / Share your thoughts